An Open-Label Phase 2 Study of Itacitinib
(INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis, NCT03144687, NCT03144687
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.
MORE DETAILS ON THIS HEMATOLOGY TRIAL:
17085 / INCB 39110-209 / STAR Trial. Trial can be opened at any location as patients are identified. / Open 10-26-2017
TRIAL AVAILABLE AT THESE LOCATIONS:
All RMCC Locations